IL259479B - Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor - Google Patents
Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitorInfo
- Publication number
- IL259479B IL259479B IL259479A IL25947918A IL259479B IL 259479 B IL259479 B IL 259479B IL 259479 A IL259479 A IL 259479A IL 25947918 A IL25947918 A IL 25947918A IL 259479 B IL259479 B IL 259479B
- Authority
- IL
- Israel
- Prior art keywords
- fucose
- deoxy
- fluoro
- combination
- cancer treatment
- Prior art date
Links
- SQTFKIKSQNCWGJ-KCDKBNATSA-N (2s,3r,4r,5s)-2-fluoro-3,4,5-trihydroxyhexanal Chemical compound C[C@H](O)[C@@H](O)[C@@H](O)[C@H](F)C=O SQTFKIKSQNCWGJ-KCDKBNATSA-N 0.000 title 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562263228P | 2015-12-04 | 2015-12-04 | |
| US201662308583P | 2016-03-15 | 2016-03-15 | |
| US201662321857P | 2016-04-13 | 2016-04-13 | |
| PCT/US2016/064783 WO2017096274A1 (en) | 2015-12-04 | 2016-12-02 | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL259479A IL259479A (en) | 2018-07-31 |
| IL259479B true IL259479B (en) | 2022-03-01 |
Family
ID=58797961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL259479A IL259479B (en) | 2015-12-04 | 2018-05-21 | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20180353524A1 (OSRAM) |
| EP (1) | EP3383404A4 (OSRAM) |
| JP (1) | JP6906520B2 (OSRAM) |
| KR (1) | KR20180086233A (OSRAM) |
| CN (1) | CN108289903B (OSRAM) |
| AU (1) | AU2016362993A1 (OSRAM) |
| BR (1) | BR112018011261A2 (OSRAM) |
| CA (1) | CA3005997A1 (OSRAM) |
| EA (1) | EA201891340A1 (OSRAM) |
| IL (1) | IL259479B (OSRAM) |
| MX (1) | MX385283B (OSRAM) |
| SG (2) | SG11201804263PA (OSRAM) |
| WO (1) | WO2017096274A1 (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2608796B1 (en) | 2010-08-05 | 2018-11-21 | Seattle Genetics, Inc. | Inhibition of protein fucosylation in vivo using fucose analogs |
| KR102576042B1 (ko) | 2016-10-11 | 2023-09-07 | 아게누스 인코포레이티드 | 항-lag-3 항체 및 이의 사용 방법 |
| MX2019014584A (es) * | 2017-06-07 | 2020-02-07 | Seattle Genetics Inc | Celulas t con fucosilacion de superficie reducida y metodos para preparar y usar las mismas. |
| WO2019075449A1 (en) * | 2017-10-13 | 2019-04-18 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | FUCOSYLATION AND IMMUNOSURVEILLANCE OF MELANOMA |
| JP2021534196A (ja) | 2018-08-23 | 2021-12-09 | シージェン インコーポレイテッド | 抗ｔｉｇｉｔ抗体 |
| WO2020132096A1 (en) * | 2018-12-19 | 2020-06-25 | Seattle Genetics, Inc. | Controlled fucosylation of antibodies |
| US20220305038A1 (en) * | 2019-08-16 | 2022-09-29 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Fucosylation and immune modulation in cancer |
| CN111973749B (zh) * | 2020-09-07 | 2023-03-21 | 威海人生药业集团股份有限公司 | 一种抗肿瘤免疫治疗的药物组合物 |
| US12036286B2 (en) | 2021-03-18 | 2024-07-16 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| US20240197761A1 (en) * | 2021-04-16 | 2024-06-20 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Fucosylation and immune modulation in cancer |
| CN113274502B (zh) * | 2021-05-05 | 2023-01-03 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 用于特定型三阴乳腺癌免疫治疗的组合物 |
| US20240238318A1 (en) * | 2021-05-06 | 2024-07-18 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | L-fucose and anti-androgen receptor therapy for treatment of cancer |
| CN113413465B (zh) * | 2021-06-15 | 2022-06-03 | 北京大学 | 岩藻糖基化抑制剂在抗癌导致炎症中的应用 |
| CN115466297B (zh) * | 2022-08-25 | 2023-07-07 | 青岛农业大学 | L-岩藻糖的应用以及动物饲料 |
| WO2024077106A2 (en) * | 2022-10-04 | 2024-04-11 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Leveraging l-fucose-mediated signaling to induce monocyte-derived dendritic cell polarization |
| WO2024191807A1 (en) | 2023-03-10 | 2024-09-19 | Seagen Inc. | Methods of treating cancer with anti-tigit antibodies |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2608796B1 (en) * | 2010-08-05 | 2018-11-21 | Seattle Genetics, Inc. | Inhibition of protein fucosylation in vivo using fucose analogs |
| IL292510A (en) * | 2013-11-05 | 2022-06-01 | Cognate Bioservices Inc | Combinations of checkpoint inhibitors and therapeutics to treat cancer |
-
2016
- 2016-12-02 WO PCT/US2016/064783 patent/WO2017096274A1/en not_active Ceased
- 2016-12-02 CA CA3005997A patent/CA3005997A1/en not_active Abandoned
- 2016-12-02 JP JP2018528650A patent/JP6906520B2/ja active Active
- 2016-12-02 SG SG11201804263PA patent/SG11201804263PA/en unknown
- 2016-12-02 AU AU2016362993A patent/AU2016362993A1/en not_active Abandoned
- 2016-12-02 BR BR112018011261A patent/BR112018011261A2/pt not_active Application Discontinuation
- 2016-12-02 US US15/781,256 patent/US20180353524A1/en not_active Abandoned
- 2016-12-02 MX MX2018006674A patent/MX385283B/es unknown
- 2016-12-02 KR KR1020187017824A patent/KR20180086233A/ko not_active Withdrawn
- 2016-12-02 EA EA201891340A patent/EA201891340A1/ru unknown
- 2016-12-02 EP EP16871645.4A patent/EP3383404A4/en not_active Withdrawn
- 2016-12-02 CN CN201680071076.0A patent/CN108289903B/zh not_active Expired - Fee Related
- 2016-12-02 SG SG10202005298RA patent/SG10202005298RA/en unknown
-
2018
- 2018-05-21 IL IL259479A patent/IL259479B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201891340A1 (ru) | 2018-11-30 |
| MX385283B (es) | 2025-03-18 |
| BR112018011261A2 (pt) | 2018-11-21 |
| SG11201804263PA (en) | 2018-06-28 |
| SG10202005298RA (en) | 2020-07-29 |
| CN108289903A (zh) | 2018-07-17 |
| EP3383404A4 (en) | 2019-07-31 |
| MX2018006674A (es) | 2018-11-09 |
| KR20180086233A (ko) | 2018-07-30 |
| CN108289903B (zh) | 2021-08-03 |
| JP6906520B2 (ja) | 2021-07-21 |
| JP2019501145A (ja) | 2019-01-17 |
| CA3005997A1 (en) | 2017-06-08 |
| AU2016362993A1 (en) | 2018-07-12 |
| WO2017096274A1 (en) | 2017-06-08 |
| IL259479A (en) | 2018-07-31 |
| US20180353524A1 (en) | 2018-12-13 |
| EP3383404A1 (en) | 2018-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL259479B (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| FIC20250023I1 (fi) | Latsertinibi kaikissa peruspatentin suojaamissa muodoissa | |
| IL259162B (en) | Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment | |
| SI3283527T1 (sl) | Kombinirana terapija proti raku | |
| SI3256218T1 (sl) | Inhibitor kdm1a in njegova uporaba v terapiji | |
| PL2976106T3 (pl) | Terapia kombinowana obejmująca inhibitor B-Raf i drugi inhibitor | |
| DK3298845T3 (da) | Programmering i licensunderstøttet tilgang | |
| DK3456330T3 (da) | Cortexolon-17alpha-valerat til anvendelse ved behandling af tumorer | |
| SI3371165T1 (sl) | Zaviralec BTK za uporabo pri zdravljenju raka | |
| DK3230318T3 (da) | Immune checkpoint-inhibitor-kombinationer | |
| DK4119569T3 (da) | Konjugerede antisense-forbindelser til anvendelse i behandling | |
| MA41176A (fr) | Complexes radio-pharmaceutiques | |
| HUE040167T2 (hu) | Rákkezelés | |
| PL3463436T3 (pl) | Szczepionka w połączeniu z inhibitorem immunologicznego punktu kontrolnego do stosowania w leczeniu nowotworów | |
| DK3393478T3 (da) | Kombinationsterapi | |
| EP3362091A4 (en) | COMBINATION THERAPY | |
| FI20145740A7 (fi) | Sovitelma puomistossa | |
| DK3380468T3 (da) | Bis-pyridazinforbindelser og anvendelse heraf i behandling af cancer | |
| DK2979704T3 (da) | Desmoglein-3-peptider i pemphigus vulgaris | |
| DK3164195T3 (da) | Glutaminaseinhibitorterapi | |
| HK1262072A1 (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| FI10846U1 (fi) | Sovitelma saunan yhteydessä | |
| TH1501006324A (th) | การบำบัดมะเร็งด้วยไดไฮโดรพิแรซิโน-พิแรซีน | |
| BR302014001882S1 (pt) | Configuração aplicada em solado | |
| BR302014001777S1 (pt) | Configuração aplicada em solado |